Financials data is unavailable for this security.
View more
Year on year Morepen Laboratories Ltd grew revenues 19.25% from 14.18bn to 16.90bn while net income improved 148.63% from 386.75m to 961.60m.
| Gross margin | 37.86% |
|---|---|
| Net profit margin | 6.77% |
| Operating margin | 8.75% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Morepen Laboratories Ltd fell by 47.21m. However, the company earned 733.75m from its operations for a Cash Flow Margin of 4.34%. In addition the company generated 52.05m cash from financing while 833.00m was spent on investing.
| Cash flow per share | 2.94 |
|---|---|
| Price/Cash flow per share | 30.68 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items increased 144.27%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| EPS growth(5 years) | 24.01 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 143.44 |
